BioXcel Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $1,104 | $582 | $376 | $341 |
Gross Profit | 965 | 424 | -416 | -171 |
EBITDA | -15,981 | -23,851 | -19,650 | -42,992 |
EBIT | -16,058 | -23,929 | -19,728 | -43,071 |
Net Income | -8,298 | -26,791 | -22,256 | -50,486 |
Net Change In Cash | 1,104 | 582 | 376 | 341 |
Free Cash Flow | -23,174 | -17,706 | -26,863 | -37,584 |
Cash | 56,271 | 74,141 | 65,221 | 89,961 |
Basic Shares | 40,253 | 30,868 | 29,449 | 29,268 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,380 | $375 | $0 | $ |
Gross Profit | -198 | 355 | -297 | |
EBITDA | -166,015 | -157,544 | -106,638 | -82,109 |
EBIT | -166,333 | -157,871 | -106,935 | -82,297 |
Net Income | -179,053 | -171,849 | -106,630 | -82,008 |
Net Change In Cash | 1,380 | 375 | 0 | |
Cost of Revenue | -39,243 | 19,849 | 180,693 | |
Free Cash Flow | -155,026 | -135,480 | -82,598 | -66,666 |
Cash | 65,221 | 193,725 | 232,968 | 213,119 |
Basic Shares | 29,129 | 28,015 | 26,373 | 21,683 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.21 |
2024-03-31 | -$0.87 |
2023-12-31 | -$0.76 |
2023-09-30 | -$1.72 |
